209 related articles for article (PubMed ID: 29936616)
1. Decaprenyl-phosphoryl-ribose 2'-epimerase (DprE1): challenging target for antitubercular drug discovery.
Gawad J; Bonde C
Chem Cent J; 2018 Jun; 12(1):72. PubMed ID: 29936616
[TBL] [Abstract][Full Text] [Related]
2. Insights into development of Decaprenyl-phosphoryl-β-D-ribose 2'-epimerase (DprE1) inhibitors as antitubercular agents: A state of the art review.
Bonde C; Gawad J; Bonde S
Indian J Tuberc; 2022 Oct; 69(4):404-420. PubMed ID: 36460369
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship mediated molecular insights of DprE1 inhibitors: A Comprehensive Review.
Dash S; Rathi E; Kumar A; Chawla K; Joseph A; Kini SG
J Biomol Struct Dyn; 2024 Aug; 42(12):6472-6522. PubMed ID: 37395797
[TBL] [Abstract][Full Text] [Related]
4. Current Affairs, Future Perspectives of Tuberculosis and Antitubercular Agents.
Gawad J; Bonde C
Indian J Tuberc; 2018 Jan; 65(1):15-22. PubMed ID: 29332642
[TBL] [Abstract][Full Text] [Related]
5. Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis.
Kb S; Kumari A; Shetty D; Fernandes E; Dv C; Jays J; Murahari M
J Mol Graph Model; 2020 Dec; 101():107718. PubMed ID: 32949960
[TBL] [Abstract][Full Text] [Related]
6. Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies.
Bhutani I; Loharch S; Gupta P; Madathil R; Parkesh R
PLoS One; 2015; 10(3):e0119771. PubMed ID: 25789990
[TBL] [Abstract][Full Text] [Related]
7. Virtual Screening of Small Molecular Inhibitors against DprE1.
Zhang G; Guo S; Cui H; Qi J
Molecules; 2018 Feb; 23(3):. PubMed ID: 29495447
[TBL] [Abstract][Full Text] [Related]
8. Biosynthesis of D-arabinose in mycobacteria - a novel bacterial pathway with implications for antimycobacterial therapy.
Wolucka BA
FEBS J; 2008 Jun; 275(11):2691-711. PubMed ID: 18422659
[TBL] [Abstract][Full Text] [Related]
9. Functional investigation of the antitubercular drug target Decaprenylphosphoryl-β-D-ribofuranose-2-epimerase DprE1/DprE2 complex.
Sammartino JC; Morici M; Stelitano G; Degiacomi G; Riccardi G; Chiarelli LR
Biochem Biophys Res Commun; 2022 Jun; 607():49-53. PubMed ID: 35366543
[TBL] [Abstract][Full Text] [Related]
10. DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization.
Brecik M; Centárová I; Mukherjee R; Kolly GS; Huszár S; Bobovská A; Kilacsková E; Mokošová V; Svetlíková Z; Šarkan M; Neres J; Korduláková J; Cole ST; Mikušová K
ACS Chem Biol; 2015 Jul; 10(7):1631-6. PubMed ID: 25906160
[TBL] [Abstract][Full Text] [Related]
11. DprE1 Inhibitors: Enduring Aspirations for Future Antituberculosis Drug Discovery.
Yadav S; Soni A; Tanwar O; Bhadane R; Besra GS; Kawathekar N
ChemMedChem; 2023 Aug; 18(16):e202300099. PubMed ID: 37246503
[TBL] [Abstract][Full Text] [Related]
12. Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target.
Manina G; Pasca MR; Buroni S; De Rossi E; Riccardi G
Curr Med Chem; 2010; 17(27):3099-108. PubMed ID: 20629622
[TBL] [Abstract][Full Text] [Related]
13. An insight into the discovery, clinical studies, compositions, and patents of macozinone: A drug targeting the DprE1 enzyme of Mycobacterium tuberculosis.
Imran M; Khan SA; Asdaq SMB; Almehmadi M; Abdulaziz O; Kamal M; Alshammari MK; Alsubaihi LI; Hussain KH; Alharbi AS; Alzahrani AK
J Infect Public Health; 2022 Oct; 15(10):1097-1107. PubMed ID: 36122509
[TBL] [Abstract][Full Text] [Related]
14. Assay development and inhibition of the
Batt SM; Toth S; Rodriguez B; Abrahams KA; Veerapen N; Chiodarelli G; Cox LR; Moynihan PJ; Lelievre J; Fütterer K; Besra GS
Microbiology (Reading); 2023 Jan; 169(1):. PubMed ID: 36748627
[TBL] [Abstract][Full Text] [Related]
15. GtrA Protein Rv3789 Is Required for Arabinosylation of Arabinogalactan in Mycobacterium tuberculosis.
Kolly GS; Mukherjee R; Kilacsková E; Abriata LA; Raccaud M; Blaško J; Sala C; Dal Peraro M; Mikušová K; Cole ST
J Bacteriol; 2015 Dec; 197(23):3686-97. PubMed ID: 26369580
[TBL] [Abstract][Full Text] [Related]
16. Antituberculars which target decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1: state of art.
Buroni S; Pasca MR; de Jesus Lopes Ribeiro AL; Degiacomi G; Molteni E; Riccardi G
Appl Microbiol Biotechnol; 2012 May; 94(4):907-16. PubMed ID: 22526781
[TBL] [Abstract][Full Text] [Related]
17. High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors.
Christophe T; Jackson M; Jeon HK; Fenistein D; Contreras-Dominguez M; Kim J; Genovesio A; Carralot JP; Ewann F; Kim EH; Lee SY; Kang S; Seo MJ; Park EJ; Skovierová H; Pham H; Riccardi G; Nam JY; Marsollier L; Kempf M; Joly-Guillou ML; Oh T; Shin WK; No Z; Nehrbass U; Brosch R; Cole ST; Brodin P
PLoS Pathog; 2009 Oct; 5(10):e1000645. PubMed ID: 19876393
[TBL] [Abstract][Full Text] [Related]
18. DprE1--from the discovery to the promising tuberculosis drug target.
Mikusová K; Makarov V; Neres J
Curr Pharm Des; 2014; 20(27):4379-403. PubMed ID: 24245764
[TBL] [Abstract][Full Text] [Related]
19. Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.
Foo CS; Lechartier B; Kolly GS; Boy-Röttger S; Neres J; Rybniker J; Lupien A; Sala C; Piton J; Cole ST
Antimicrob Agents Chemother; 2016 Nov; 60(11):6451-6459. PubMed ID: 27527085
[TBL] [Abstract][Full Text] [Related]
20. Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.
Chikhale RV; Barmade MA; Murumkar PR; Yadav MR
J Med Chem; 2018 Oct; 61(19):8563-8593. PubMed ID: 29851474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
